The mission of the EU-funded TISSUEGEN
project is the production of an in vitro human disease
tissue platform technology to enable the development of regenerative medicine therapies
.The concept is based on the in vitro generation of 3D human tissues
cultured from human IPSCs.Liver hepatocytes
and tissues have been designated for the validation phase due to their scientific and commercial significance.During the first stage of the four-year project partners produced an IPSC library
from an inherited metabolic liver disorder
donor set and developed key parameters
of human pluripotent stem cell
These cells and human hepatocytes have been loaded onto the 3D liver tissue platform.
Work has focused on optimisation of the conditions for the loading of the hepatocytes onto current 3D scaffolds and assessment of hepatocyte functionality over an extended period.Results and achievements of the project have so far been presented in five high-impact publications in peer-reviewed journals.
A successful platform will mean that regenerative therapies can be assessed in a scalable, cost-effective format.3D modelling cancer tissue modelling also promises to increase understanding of these diseases.
Provided by Cordis